ReviewPLoS pathogens2019
Casting a wider net: Immunosurveillance by nonclassical MHC molecules.
Review in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.Nature reviews. Immunology · 2026Review
- Herpesvirus-host interactions in neurological diseases: the immunogenetic role of HLA-E.Journal of virology · 2025Review
- Inbreeding does not reduce major histocompatibility complex diversity in the banded mongoose.BMC ecology and evolution · 2025Article
- consHLA: a next generation sequencing consensus-based HLA typing workflow.BMC bioinformatics · 2025Article
- B cell-expressed CD1d promotes MPL/TDCM lipid emulsion adjuvant effects in polysaccharide vaccines.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.Vaccines · 2025Review
- CD1-restricted T cells: are unconventional allies the key to future TB vaccines?Frontiers in immunology · 2025Review
- Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines.Nature communications · 2024Article
- Only rare classical MHC-I alleles are highly expressed in the European house sparrow.Proceedings. Biological sciences · 2024Article
- Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRs.Frontiers in oncology · 2024Article
- Implications of MHC-restricted immunopeptidome in transplantation.Frontiers in immunology · 2024Review
- Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies.Frontiers in immunology · 2024Review
- Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.Cancers · 2023Review
- γδ T cells: origin and fate, subsets, diseases and immunotherapy.Signal transduction and targeted therapy · 2023Review
- Intracellular trafficking of HLA-E and its regulation.The Journal of experimental medicine · 2023Article
- Review
- Murine cytomegalovirus downregulates ERAAP and induces an unconventional T cell response to self.Cell reports · 2023Article
- Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and commonFrontiers in immunology · 2023Article
- Conventional and non-conventional antigen presentation by mast cells.Discovery immunology · 2023Review
- Determinants of tumor immune evasion: the role of T cell exposed motif frequency and mutant amino acid exposure.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Most studies of T lymphocytes focus on recognition of classical major histocompatibility complex (MHC) class I or II molecules presenting oligopeptides, yet there are numerous variations and exceptions of biological significance based on recognition of a wide variety of nonclassical MHC molecules. These include αβ and γδ T cells that recognize different class Ib molecules (CD1, MR-1, HLA-E, G, F, et al.) that are nearly monomorphic within a given species. Collectively, these T cells can be considered "unconventional," in part because they recognize lipids, metabolites, and modified peptides. Unlike classical MHC-specific cells, unconventional T cells generally exhibit limited T-cell antigen receptor (TCR) repertoires and often produce innate immune cell-like rapid effector responses. Exploiting this system in new generation vaccines for human immunodeficiency virus (HIV), tuberculosis (TB), other infectious agents, and cancer was the focus of a recent workshop, "Immune Surveillance by Non-classical MHC Molecules: Improving Diversity for Antigens," sponsored by the National Institute of Allergy and Infectious Diseases. Here, we summarize salient points presented regarding the basic immunobiology of unconventional T cells, recent advances in methodologies to measure unconventional T-cell activity in diseases, and approaches to harness their considerable clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.